Seraseq® ctDNA MRD 0.05% TumorMRD monitoring typically involves measuring signs of a cancer in order to inform decisions about treatment escalation and de escalation. Typically, this can be facilitated by use of less invasive techniques such as liquid biopsy (ctDNA), to monitor cancer specific somatic variants. A patient derived approach to the application of ctDNA based MRD monitoring starts with a tumor profiling analysis to identify clinically relevant tumor variants that